Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront for the Non-opioid Neuropathic Pain Treatment, NRD.E1, for Greater China and Singapore
Novaremed AG and NeuroFront Therapeutics (Hong Kong) Limited jointly announce the signing of an exclusive collaboration and commercialization agreement for Novaremed’s innovative non-opioid investigational drug, NRD.E1, being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications. Under the terms of the agreement, Novaremed is eligible to receive from NeuroFront over USD 130 million in option and exercise fees as well as development, regulatory and sales milestone payments plus royalties on net sales.
Under the terms of the agreement, Novaremed will grant NeuroFront an exclusive option to obtain exclusive development, commercialization and manufacturing rights to NRD.E1, Novaremed’s first-in-class, innovative non-opioid investigational drug candidate for the treatment of neuropathic pain. The agreement allows NeuroFront to develop and commercialize NRD.E1 as treatment of painful diabetic peripheral neuropathy (PDPN) and any other neuropathic pain indications in the Greater China territory (including Mainland China, Hong Kong, Macau, and Taiwan) and Singapore.
NeuroFront has the right to exercise its license option at its discretion, but no later than upon completion of the Phase 2b trial of NRD.E1 in PDPN, which will start patient enrollment in coming weeks.
In case NeuroFront successfully develops and registers NRD.E1 in additional neuropathic pain indications in the licensed territory, Novaremed is also eligible to receive additional development and regulatory milestone payments for each additional indication.
“We are very delighted collaborating with NeuroFront to advance our non-opioid neuropathic pain treatment for patients suffering from PDPN and other neuropathic pain indications in China. Currently, approved medications for PDPN provide inadequate pain relief and are associated with many intolerable side effects. Based on both preclinical and clinical data, we believe NRD.E1 has the potential to offer unique benefits and revolutionize the way PDPN is treated,” said Isaac Kobrin, MD, Executive Chairman of Novaremed. “NeuroFront’s development and commercial expertise and its focus on innovative CNS drugs is complementary to our expertise and an ideal fit for Novaremed.”
“There are up to 19 million patients suffering from PDPN in China, but no new innovative drug has been introduced in the market for more than 15 years. There exists a significant unmet medical need and hence a great opportunity for NRD.E1, a first-in-class, novel treatment that has already demonstrated clinical effectiveness in a Phase 2a clinical trial and subsequently received US FDA Fast Track Designation and NIH sponsorship for its Phase 2b trial,” said June Yan, CEO of NeuroFront. “NeuroFront is very excited to partner with Novaremed to change the lives of many PDPN patients in Greater China and Singapore.”
This partnership and the transaction were facilitated with the assistance of Cukierman and Company Investment House.
About NRD.E1 and the treatment of chronic pain
NRD.E1 is an orally active small molecule with a novel mechanism of action by modulating Lyn kinase and has patent protection until 2040. NRD.E1 is Novaremed’s lead drug candidate currently being developed to treat painful diabetic peripheral neuropathy (PDPN). Novaremed successfully completed three Phase 1 studies [1] and one double-blind, placebo-controlled Phase 2a dose-finding proof-of-concept study [2] in which NRD.E1 showed a clinically relevant reduction in patient-reported pain (measured as an improvement in mean neuropathic pain score) and was very well tolerated at all doses tested.
On the basis of these results, NRD.E1 has been granted Fast Track Designation by the US FDA and was selected by the National Institutes of Health (NIH) in the US as the only oral agent to be included in the NIH-HEAL (Help End Long-term Addiction) program. The NIH will sponsor and execute a 12-week, double-blind, placebo-controlled Phase 2b study in patients with moderate to severe PDPN in the US. Recruitment into this clinical trial will start in coming weeks.
About NeuroFront
NeuroFront is a China-based clinical stage neuroscience biotech company with a focus on developing and commercializing innovative neuroscience therapies to address unmet needs and improve patients' lives in China and Asia. NeuroFront was established by top-tier life sciences investors, including Nan Fung Life Sciences and Pivotal bioVenture Partners China, and is led by an elite team of neuroscience industry veterans with substantial and compelling expertise in China and globally in both R&D and the commercialization of CNS products. NeuroFront is building a portfolio of innovative, transformative CNS therapies that treat migraine, painful diabetic peripheral neuropathy, depression, ADHD, and other CNS diseases with high unmet medical needs. For more information: www.neurofrontrx.com.
About Novaremed
Novaremed AG, a privately held clinical-stage biopharmaceutical company, is developing a pipeline of innovative medications for chronic pain management to address the high unmet medical need for better pain relief and as an alternative to opioids. Its lead product is NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action, has FDA Fast Track Designation and IND-approval to proceed with a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy (PDPN). The earlier stage pipeline addressing chronic neuropathic pain includes the development candidates MP-101 (Phase 2 stage), and MP-103 (preclinical stage), targeting the unmet medical need of prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN). Novaremed Ltd (Israel) and Metys Pharmaceuticals AG (Switzerland) are fully owned subsidiaries of Novaremed AG, domiciled in Basel (Switzerland). For more information: www.novaremed.com.
References
[1] Tiecke E., Rainisio M., Guentert T., Müller S., Hochman L., Kaplan E., Mangialaio S. (2022). First-in-human single-ascending-dose, multiple-dose and food interaction studies of NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy. Clinical Pharmacology in Drug Development (CPDD). (https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1103)
[2] Tiecke E., Rainisio M., Eisenberg E., Wainstein J., Kaplan E., Silverberg M., Hochman L., Mangialaio S. (2022). NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy – a randomized proof of concept study. European Journal of Pain. (https://onlinelibrary.wiley.com/doi/10.1002/ejp.1989)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005391/en/
Contact information
Contact for Novaremed
Mark Altmeyer, Executive Member of the Board
mark.altmeyer@novaremed.com
Contact for NeuroFront
Bin Yao, VP of Operations and Commercialization
bin.yao@neurofrontrx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
euNetworks Appoints Nick Walden as Chief Revenue Officer20.11.2025 11:00:00 EET | Press release
euNetworks has today announced the appointment of Nick Walden as Chief Revenue Officer, effective 02 December 2025. Nick will be based in London and will drive all facets of euNetworks’ sales and commercial strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120550034/en/ Nick Walden - CRO of euNetworks Nick joins euNetworks following 30+ years in the Telecommunications industry, most recently having led the Global Sales function for Infinera (now Nokia) as Senior Vice President – Worldwide Sales. Prior to this, Nick served as Senior Vice President & Managing Director EMEA at Infinera following over a decade of experience in leadership roles at Ciena. “It’s an incredibly exciting time to be joining euNetworks, building on their strong growth and momentum as a critical bandwidth infrastructure provider across Europe. euNetworks’ relentless customer obsession aligns closely with my passion for delivering value for cust
MVNO Europe calls on the European Commission to enable a true Single Market for mobile connectivity and Internet of Things (IoT) through the Digital Networks Act20.11.2025 10:56:00 EET | Press release
The upcoming legislative proposal for a Digital Networks Act (DNA) marks a defining moment for the European Union to build a true Single Market for electronic communications based on openness, competition and innovation. MVNO Europe believes the upcoming DNA should build on the achievements of the existing EU regulatory framework by strengthening competition among diverse providers. This competition drives innovation and delivers tangible benefits for European consumers and businesses. Ensuring genuine choice for end users is essential to maintain Europe’s global competitiveness. In light of the DNA, MVNO Europe stresses the importance of preserving and reinforcing key aspects of the European Electronic Communications Code (EECC): Maintaining the Significant Market Power (SMP) regime is essential to safeguard competition. MVNO Europe calls for the express ability to apply SMP rules to any markets, including mobile markets, as it is vital to prevent abuse of dominant market positions an
Breker Verification Systems and Frontgrade Gaisler Collaborate on High-Reliability RISC-V Fault Tolerant Processor Core20.11.2025 10:00:00 EET | Press release
Breker Verification Systems, whose portfolio solves challenges across the functional verification process for large, complex semiconductors and Frontgrade™ Technologies, a leading provider of high-reliability electronic solutions for space and national security missions today confirmed its RISC-V functional verification solutions were pivotal for verification of the NOEL-V, one of Frontgrade Gaisler’s fault-tolerant RISC-V processor IP cores. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120600508/en/ “The development of Frontgrade Gaisler’s IP cores is guided by a philosophy that does not tolerate design issues,” notes Jan Andersson, Director of Engineering at Frontgrade Gaisler. “This demands the most robust verification environment, something Breker’s verification solution has contributed to improve, with its broad range of tests and in-depth corner case coverage.” The ultra-high verification coverage afforded by Brek
Verne and Nscale Announce 15MW AI Infrastructure Deployment to Accelerate Sustainable AI Infrastructure Growth in the Nordics20.11.2025 10:00:00 EET | Press release
Verne, the leading provider of low-carbon high-performance data centres across the Nordics, has signed a 15-megawatt agreement with Nscale, the hyperscaler engineered for AI. This collaboration marks a significant step in expanding sustainable AI capacity in Europe. The agreement will feature approximately 4,600 NVIDIA Blackwell Ultra GPUs deployed across Verne’s Icelandic campus throughout 2026. The configuration will be 85 percent liquid-cooled and 15 percent air-cooled, optimised for efficiency and density within Verne’s existing infrastructure. This project is one of the region’s largest liquid-cooled GPU installations, setting a new standard for sustainable high-performance computing by reducing energy use and environmental impact. Dominic Ward, CEO, Verne, said: “The pace of change in AI infrastructure is extraordinary. As the demand for GPU capacity accelerates, availability of clean, renewable power has become as important as raw performance. Partnering with Nscale, whose exper
Yagi & Co., Ltd.: Exhibiting for the first time at ISPO Munich 2025, the world's largest trade fair for sports goods, based in Germany20.11.2025 10:00:00 EET | Press release
Yagi & Co., Ltd. (TOKYO:7460) (https://www.yaginet.co.jp/en/index.html) will be exhibiting for the first time at ISPO Munich, held in Munich, Germany, over three days from Sunday 30th November to Tuesday 2nd December this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119473772/en/ Since ancient times, the lava rock formed beneath Mt. Fuji has been carefully protected from changes in surface temperature and weathering. LAVATECH is made by weaving this high-quality underground lava rock. We have achieved a high far-infrared effect by using a special technology to finely crush the lava rock that lies underground at Mt. Fuji for weaving into fibers. This brand of materials enables the creation of new products that address a wide range of health issues in areas such as sleep, beauty and sports through their blood circulation-promoting effects. About ISPO Based in Germany, it is one of the world's largest trade fairs spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom